The high prevalence of uterine fibroids among women is likely to drive the uterine fibroids treatment market in the United States to new heights throughout the forecast period
Uterine fibroids are noncancerous uterine growths that commonly arise during pregnancy. Uterine fibroids, also known as leiomyomas (lie-o-my-O-muhs) or myomas, aren't linked to an elevated risk of uterine cancer and almost never turn cancerous. Fibroids range in size from tiny seedlings that are undetectable to enormous masses that deform and expand the uterus. A single fibroid or a group of them can be present. Multiple fibroids can cause the uterus to enlarge to the point where it reaches the rib cage, causing weight gain. Uterine fibroids affect many women at some point in their lives. However, because uterine fibroids rarely cause symptoms, you may be unaware that you have them. During a pelvic exam or a pregnancy ultrasound, your doctor may uncover fibroids by chance. U.S. uterine fibroids treatment market is estimated to account for US$ 243.5 Mn in terms of value in 2020 and is expected to reach US$ 298.5 Mn by the end of 2027. The U.S. uterine fibroids treatment market ...